Kaempferol as a therapeutic agent in Alzheimer?s disease: Evidence from preclinical studies

被引:28
|
作者
Dong, Xiaoyu [1 ]
Zhou, Siyu [1 ]
Nao, Jianfei [1 ]
机构
[1] China Med Univ, Shengjing Hosp, Dept Neurol, 36 Sanhao St, Shenyang 110004, Liaoning, Peoples R China
关键词
Kaempferol; Alzheimer?s disease; Natural sources; A; Neuroprotection; Systematic review; AMYLOID-BETA PEPTIDE; OXIDATIVE STRESS; RAT MODEL; CELLS; MECHANISM; PLAQUE; NEUROINFLAMMATION; NEUROTOXICITY; MODULATION; QUERCETIN;
D O I
10.1016/j.arr.2023.101910
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: Alzheimer's disease (AD) is the most common type of dementia and seriously affects human life and health. Kaempferol (KMP) is a common flavonoid, that is mainly derived from the rhizomes of Kaempferol galanga L. and is widely found in various fruits and vegetables. Previous studies have suggested that KMP has multiple pharmacological activities. However, the anti-AD mechanism of KMP has not been elucidated.Methods: This systematic review aims to summarize the existing preclinical experiments on KMP, further confirm the therapeutic effect of KMP in an AD model, and summarize the possible mechanism by which KMP exerts anti -AD effects. Electronic databases, including PubMed, China National Knowledge Infrastructure (CNKI), Baidu Academic, and Wanfang, were searched using the keywords of 'Kaempferol,' 'KMP,' 'pharmacology,' and 'Alz-heimer's disease'.Results: We evaluated the reliability of the 12 included studies, and the results showed that the anti-AD mech-anism of KMP was reliable and that the prospect of KMP in the treatment of cognitive impairment was promising. We comprehensively assessed the neuroprotective effects of KMP in in vivo and in vitro models of AD. These studies shown that KMP ameliorated AD through several mechanisms, including its antioxidant, anti-inflammatory, anti-apoptotic, and anti-acetylcholinesterase effects.Conclusion: KMP may exert anti-AD effects through various mechanisms and is a potential drug with broad prospects for the treatment of AD.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease
    Goyal, Ahsas
    Verma, Aanchal
    Dubey, Nandini
    Raghav, Jyoti
    Agrawal, Anant
    JOURNAL OF FOOD BIOCHEMISTRY, 2022, 46 (12)
  • [22] Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer's disease? From preclinical studies to the clinical trials
    Basheer, Neha
    Smolek, Tomas
    Hassan, Imtaiyaz
    Liu, Fei
    Iqbal, Khalid
    Zilka, Norbert
    Novak, Petr
    MOLECULAR PSYCHIATRY, 2023, 28 (06) : 2197 - 2214
  • [23] Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease
    de Leon, M. J.
    Mosconi, L.
    Blennow, K.
    DeSanti, S.
    Zinkowski, R.
    Mehta, P. D.
    Pratico, D.
    Tsui, W.
    Saint Louis, L. A.
    Sobanska, L.
    Brys, M.
    Li, Y.
    Rich, K.
    Rinne, J.
    Rusinek, H.
    IMAGING AND THE AGING BRAIN, 2007, 1097 : 114 - 145
  • [24] Preclinical Alzheimer's disease
    Gil-Gregorio, P.
    Yubero-Pancorbo, R.
    REVIEWS IN CLINICAL GERONTOLOGY, 2014, 24 (02) : 117 - 121
  • [25] Thematic Review Series: ApoE and Lipid Homeostasis in Alzheimer's Disease Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies
    Shinohara, Mitsuru
    Tachibana, Masaya
    Kanekiyo, Takahisa
    Bu, Guojun
    JOURNAL OF LIPID RESEARCH, 2017, 58 (07) : 1267 - 1281
  • [26] Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer's Disease
    Beggiato, Sarah
    Tomasini, Maria Cristina
    Ferraro, Luca
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [27] Evaluation of bumetanide as a potential therapeutic agent for Alzheimer's disease
    Boyarko, Ben
    Podvin, Sonia
    Greenberg, Barry
    Momper, Jeremiah D. D.
    Huang, Yadong
    Gerwick, William H. H.
    Bang, Anne G. G.
    Quinti, Luisa
    Griciuc, Ana
    Kim, Doo Yeon
    Tanzi, Rudolph E. E.
    Feldman, Howard H. H.
    Hook, Vivian
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [28] Donepezilium oxalate trihydrate, a therapeutic agent for Alzheimer's disease
    Ravikumar, K.
    Sridhar, B.
    Sathe, D. G.
    Naidu, A. V.
    Sawant, K. D.
    ACTA CRYSTALLOGRAPHICA SECTION C-STRUCTURAL CHEMISTRY, 2006, 62 : O681 - O683
  • [29] Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease
    Bai, DL
    Tang, XC
    He, XC
    CURRENT MEDICINAL CHEMISTRY, 2000, 7 (03) : 355 - 374
  • [30] Alzheimer's disease and gut microbiota modifications: The long way between preclinical studies and clinical evidence
    Mancuso, Cesare
    Santangelo, Rosaria
    PHARMACOLOGICAL RESEARCH, 2018, 129 : 329 - 336